EMEA-000402-PIP02-11-M05
Key facts
Invented name |
Vimpat
|
Active substance |
lacosamide
|
Therapeutic area |
Neurology
|
Decision number |
P/0001/2018
|
PIP number |
EMEA-000402-PIP02-11-M05
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of epilepsy with partial-onset seizures
|
Route(s) of administration |
|
Contact for public enquiries |
UCB Pharma S.A.
Tel. +44 1753677251 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-000402-PIP02-11-M05
|
Compliance opinion date |
27/07/2018
|
Compliance outcome |
positive
|